JP2020517294A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517294A5
JP2020517294A5 JP2019558615A JP2019558615A JP2020517294A5 JP 2020517294 A5 JP2020517294 A5 JP 2020517294A5 JP 2019558615 A JP2019558615 A JP 2019558615A JP 2019558615 A JP2019558615 A JP 2019558615A JP 2020517294 A5 JP2020517294 A5 JP 2020517294A5
Authority
JP
Japan
Prior art keywords
gpc3
amino acid
seq
acid sequence
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019558615A
Other languages
English (en)
Japanese (ja)
Other versions
JP7295030B2 (ja
JP2020517294A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/029221 external-priority patent/WO2018200586A1/en
Publication of JP2020517294A publication Critical patent/JP2020517294A/ja
Publication of JP2020517294A5 publication Critical patent/JP2020517294A5/ja
Priority to JP2023094432A priority Critical patent/JP2023123540A/ja
Application granted granted Critical
Publication of JP7295030B2 publication Critical patent/JP7295030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019558615A 2017-04-26 2018-04-24 グリピカン3を特異的に認識するコンストラクト及びその使用 Active JP7295030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023094432A JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490586P 2017-04-26 2017-04-26
US62/490,586 2017-04-26
PCT/US2018/029221 WO2018200586A1 (en) 2017-04-26 2018-04-24 Constructs specifically recognizing glypican 3 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023094432A Division JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Publications (3)

Publication Number Publication Date
JP2020517294A JP2020517294A (ja) 2020-06-18
JP2020517294A5 true JP2020517294A5 (enExample) 2021-06-10
JP7295030B2 JP7295030B2 (ja) 2023-06-20

Family

ID=63920003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558615A Active JP7295030B2 (ja) 2017-04-26 2018-04-24 グリピカン3を特異的に認識するコンストラクト及びその使用
JP2023094432A Pending JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023094432A Pending JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Country Status (15)

Country Link
US (2) US11447564B2 (enExample)
EP (1) EP3615574A4 (enExample)
JP (2) JP7295030B2 (enExample)
KR (2) KR102663596B1 (enExample)
CN (1) CN110741019B (enExample)
AU (1) AU2018258049B2 (enExample)
CA (1) CA3059820A1 (enExample)
IL (2) IL319308A (enExample)
MX (2) MX420947B (enExample)
MY (1) MY201065A (enExample)
PH (1) PH12019502412A1 (enExample)
SG (2) SG10201913582XA (enExample)
TW (1) TWI878207B (enExample)
WO (1) WO2018200586A1 (enExample)
ZA (1) ZA202000027B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070608A1 (en) 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
MX420947B (es) 2017-04-26 2025-02-10 Eureka Therapeutics Inc Constructos que reconocen específicamente glipicano 3 y usos de estos.
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
ES2901683T3 (es) * 2018-12-21 2022-03-23 Kymab Ltd Anticuerpo biespecífico FIXAXFX con cadena ligera común
EP3919517A4 (en) * 2019-02-01 2023-03-15 CRAGE medical Co., Limited TCR FUSION PROTEIN AND CELL WITH TCR FUSION PROTEIN EXPRESSION
EP3965897A4 (en) * 2019-05-07 2023-01-04 The Board of Trustees of the Leland Stanford Junior University CHEMERA ANTIGEN RECEPTORS TARGETING GLYPICAN-2
US12109235B2 (en) 2019-06-21 2024-10-08 Kite Pharma, Inc. TGF-beta receptors and methods of use
EP4065606A4 (en) * 2019-11-26 2023-08-02 Ramot at Tel-Aviv University Ltd. CHIMERIC ANTIGEN RECEPTOR FOR CARBOHYDRATES
JP7822313B2 (ja) * 2019-12-20 2026-03-02 メディミューン,エルエルシー グリピカン3を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
JP2023514232A (ja) * 2020-02-14 2023-04-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Cd2活性化を伴うキメラ抗原受容体
EP4110912A4 (en) * 2020-02-27 2024-07-10 Legend Biotech Ireland Limited ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND METHODS OF USE THEREOF
JP7778081B2 (ja) * 2020-03-18 2025-12-01 ユーティレックス カンパニー リミテッド Il-18を分泌するgpc3 car-t細胞、並びにそれを作製する方法及び使用する方法
BR112022020716A2 (pt) * 2020-05-07 2022-11-29 Phanes Therapeutics Inc Anticorpos anti-tumor associados ao antígeno e usos dos mesmos
WO2021261597A1 (ja) * 2020-06-26 2021-12-30 協和キリン株式会社 GPC3とTfRに結合するバイスペシフィック抗体
US20240199759A1 (en) * 2021-04-05 2024-06-20 Cytovia Therapeutics, Llc. Bispecific antibodies targeting nkp46 and gpc3 and methods of use thereof
IL307923A (en) * 2021-04-23 2023-12-01 Shanghai Henlius Biotech Inc Anti-gpc3 antibodies, multispecific antibodies and methods of use
CN113203780B (zh) * 2021-05-13 2022-05-31 桂林电子科技大学 一种非诊断目的无标记适配体传感器检测gpc3的方法
CN113238040B (zh) * 2021-05-18 2022-05-31 桂林电子科技大学 一种非诊断目的基于纳米复合材料的laps传感器检测gpc3方法
EP4341294A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
AU2022291365B2 (en) * 2021-06-08 2026-03-12 Kite Pharma, Inc. Gpc3 binding molecules
WO2023061505A1 (en) * 2021-10-15 2023-04-20 Concept To Medicine Biotech Co., Ltd. Anti-glypican 3 antibodies
WO2023215738A1 (en) * 2022-05-02 2023-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
WO2023249071A1 (ja) * 2022-06-24 2023-12-28 国立研究開発法人国立がん研究センター T細胞受容体
TW202413646A (zh) * 2022-07-22 2024-04-01 美商萊爾免疫藥物股份有限公司 免疫細胞療法
KR20250110345A (ko) * 2022-11-21 2025-07-18 비원 메디슨즈 아이 게엠베하 항-cd137 항체 및 사용 방법
WO2025159562A1 (ko) * 2024-01-24 2025-07-31 국립암센터 Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
ATE120457T1 (de) 1988-06-24 1995-04-15 Dow Chemical Co Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikörper.
ZA894792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン コーポレーション Hiv感染治療のための異種複合抗体
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
DK1071752T3 (da) 1998-04-21 2003-10-20 Micromet Ag CD19xCD3-specifikke polypeptider og anvendelsen deraf
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1242049A4 (en) 1999-12-13 2005-01-05 Epimmune Inc VACCINE COMPOSITIONS AND ANTIGEN PEPTIDES ASSOCIATED WITH CLASS I HLA-A2 TUMOR
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE60229246D1 (enExample) 2001-05-26 2008-11-20 One Cell Systems Inc
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化n端ペプチドに対する抗体
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
PL1674111T3 (pl) 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP5868593B2 (ja) 2007-07-17 2016-02-24 メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. Glypican−3に対するモノクローナル抗体
EP2225277A4 (en) 2007-11-27 2012-03-14 Viventia Biotech Inc ANTIBODIES TO A CANCER-ASSOCIATED EPITOPE OF THE VARIANT NFKBIB AND APPLICATIONS THEREOF
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US9637557B2 (en) 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
CN103596985B (zh) * 2011-04-19 2016-06-08 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
CN104093744A (zh) 2011-10-11 2014-10-08 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014138314A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN104140974B (zh) 2013-05-08 2017-09-29 科济生物医药(上海)有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
RU2016150370A (ru) * 2014-05-22 2018-06-26 Дженентек, Инк. Антитела и иммуноконъюгаты против GPC3
US10093746B2 (en) * 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
ES2844700T3 (es) * 2014-09-26 2021-07-22 Baylor College Medicine Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
RU2021124437A (ru) * 2015-04-03 2021-09-29 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
MX2017014822A (es) 2015-05-18 2018-04-30 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
WO2017070608A1 (en) 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2017382902A1 (en) 2016-12-21 2019-07-18 TCR2 Therapeutics Inc. Engineered T cells for the treatment of cancer
EP3579877A4 (en) 2017-02-09 2020-12-09 The Regents of The University of California CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE
MX420947B (es) 2017-04-26 2025-02-10 Eureka Therapeutics Inc Constructos que reconocen específicamente glipicano 3 y usos de estos.
EP3638295A1 (en) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102061677B1 (ko) 2018-08-23 2020-02-11 주식회사 나노테크 텅스텐과 티타늄 복합 탄화물 분말의 제조 방법

Similar Documents

Publication Publication Date Title
JP2020517294A5 (enExample)
JP7748933B2 (ja) 抗dll3キメラ抗原受容体及びその使用
RU2558301C2 (ru) Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
JP6557657B2 (ja) 分子
JP2018512145A5 (enExample)
AU2016262662A1 (en) Antibodies that bind csf1r
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
JP2024023228A5 (enExample)
CN111378044B (zh) 抗体融合蛋白、制备方法及其应用
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
CN115066274A (zh) 三价结合分子
JP2021528382A (ja) 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段
CN104628866A (zh) 一种靶向vegfr2的抗体融合蛋白的制备及其用途
JPWO2021184673A5 (enExample)
CN115279792A (zh) 对bcma特异的抗体及嵌合抗原受体
TW202309083A (zh) 抗cldn4-抗cd137雙特異性抗體
CN113227127A (zh) 向胃肠系统递送酬载的btnl3/8导引构建体
US20210363265A1 (en) Multivalent receptor-clustering agonist antibody constructs
CN110938146B (zh) Tim-3单域抗体及其应用
JP2023116826A (ja) 抗原結合分子
JPWO2021139758A5 (enExample)
KR20240082403A (ko) 항-bcma 단일 도메인 항체 및 치료 작제물
CN120112555A (zh) 抗vista单克隆抗体及其用途
EP3014271A1 (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
US20260049118A1 (en) Single-chain chimeric polypeptides and uses thereof